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Abstract   
Background: The impact of COVID-19 may be more severe in developing countries. Our study aims to analyze the 
accuracy of several inflammatory biomarkers in predicting COVID-19 mortality, providing information about the most 
suitable markers for developing countries. 
Methods: A retrospective cohort study was conducted at Dr. Soetomo General Hospital, Indonesia, from March to 
June 2020. White Blood Cells (WBC) count, Neutrophil-Lymphocyte Ratio (NLR), Procalcitonin (PCT), D-Dimer, and 
C-Reactive Protein (CRP) have been collected from the electronic medical records. We performed survival analysis to 
provide the hazard ratio and Receiver Operating Characteristic (ROC) curve analysis to test for accuracy for each 
parameter. 
Results: A total of 423 patients who met the criteria for participating had a median age of 54 (IQR 45-61) years. 
Patients in the death group are characterized by older age and shorter length of hospitalization. The WBC, NLR, PCT, 
D-Dimer, and CRP are found significantly higher in the death group (P=0.000). The WBC, NLR, PCT, D-Dimer, and 
CRP have an Area Under the Curve (AUC) of 0.709, 0.773, 0.738, 0.721, and 0.769, respectively moderate accuracy 
in predicting COVID-19 patient mortality. We found that NLR is significantly more accurate than the age parameter 
(Z=3.527; P=0.000) but has equal accuracy with other laboratory parameters. 
Conclusion: Since NLR obtained the highest accuracy, we still recommend routine complete blood count tests as 
prognostic biomarkers with the highest feasibility to be performed in developing countries. 
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Background  
Coronavirus Disease 2019 (COVID-19) has been one of the 
most significant global pandemics. Recently, on July 27th, 
2021, Indonesia contributed the third-highest number of new 
COVID-19 cases in the world [1]. The exponential increase of 
COVID-19 patients is also found in Indonesia, with 3,532,567 
cases and 100,636 deaths as of August 4th, 2021 [2]. Therefore, 
Indonesia, and other developing countries, must increase 
awareness and develop the most well-suited guidelines for 
COVID-19 management. The early identification can provide 
necessary information for managing COVID-19 patients [3,4]. 
A previous study showed an association between several 
biomarkers to the severity and mortality of COVID-19 patients 
[5–7]. Early laboratory examinations are necessary to predict 
worsened outcomes and prepare the most advisable 
management for patients [5,8]. However, few studies from a 
large developing country like Indonesia reported early 
laboratory examination on predicting survival and mortality. 
The white blood cell count (WBC) and neutrophil-lymphocyte 
ratio (NLR) have been recognized as routine hematological 
markers that have been used widely in clinical settings [9,10]. 
The WBC and NLR have good predictive accuracy in 
predicting poor clinical outcomes [11,12]. However, previous 
studies show that only the newer inflammatory biomarker, 
procalcitonin (PCT), has high accuracy in predicting COVID-19 
poor outcomes in critical conditions [13]. The findings were 
also supported by one meta-analysis, showing the accuracy of 
PCT was 90.5%, while other markers (WBC, NLR, and C-
Reactive Protein (CRP)) have accuracy below 85% [14]. The 
newer inflammatory marker seems promising but has a higher 
cost and difficulty implementing primary or secondary medical 
care in developing countries. Therefore, there is a need for 
information on the difference in accuracy between the newer 
inflammatory marker and the routine, low-cost, complete blood 
count test. Our study aims to analyze the accuracy of WBC, 
NLR, PCT, D-Dimer, and CRP in predicting COVID-19 
mortality. These findings may support the decision of clinical 
management protocols in developing countries.   
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Methods    
Study Design and Participants 
This study was a retrospective cohort study of hospitalized 
patients with COVID-19 enrolled at Dr. Soetomo General 
Hospital (Surabaya City, East Java Province, Indonesia). All 
confirmed COVID-19 patients were screened, and those who 
had definite outcomes (death or discharged) between March 1st, 
2020, and June 30th, 2020, were listed. From the total of 423 
patients, then 28 pregnant patients, 8 patients with no Real-
Time Polymerase Chain Reaction (RT-PCR) test record, and 46 
patients with no early laboratory tests were excluded, leaving 
341 patients included in this study. Not all the patients received 
all parameters tests because of physicians' feasibility and 
clinical decision.  
 
Data Collection 
The age, length of hospitalization, and early laboratory test 
(WBC, neutrophil percentage, lymphocyte percentage, 
procalcitonin, D-Dimer, and CRP) were collected from 
secondary data from electronic medical records using a 
standardized data collection form. All data were checked twice 
to ensure the data retrieve correctly before being entered into a 
computerized database.  . 
 
Definitions 
The diagnosis of COVID-19 was defined according to the 
Indonesian Ministry of Health COVID-19 prevention and 
control guidelines (version 5.0) [15]. Detection of Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)  infection 
is done using real-time RT-PCR methods from nasopharyngeal 
swab specimens. The confirmative examination was conducted 
by the Diagnostic Center of Dr. Seotomo General Hospital, 
Surabaya. The criteria for discharge were complete isolation for 
ten days from the date of onset with a minimum of 3 days after 
an absence of fever and respiratory problems (for mild and 
moderate patients) or has obtained a negative one-time RT-PCR 
follow-up examination plus a minimum of 3 days after an 
absence of fever and respiratory problems (for severe and 
critical patients). The laboratory examination was conducted  
based on Dr. Soetomo General Hospital Clinical Practice 
Guidance. Neutrophil-Lymphocyte Ratio (NLR) was calculated 
by dividing the neutrophil percentage by the lymphocyte 
percentage. 
 
Statistical analysis   
The age, length of hospitalization, and laboratory data were 
presented as the median and interquartile range (IQR), while 
sex variables were presented as count (n) and percentage (%). 
The Mann-Whitney U test and Chi-square test compared 
differences between the discharge and death groups. Survival 
analysis was performed using the Kaplan-Meier survival curve 
to measure survival probability during hospitalization, showing 
the Log Rank p-value. We use the Cox proportional hazard 
regression model to determine the hazard ratio (HR) during 
hospitalization. Receiver Operating Characteristic (ROC) 
curves were conducted to measure the Area Under the Curve 
(AUC) value, sensitivity, and specificity of a predictivevariable. 
All statistic was performed individually for each variable. Since 
the difference in the sample size of each laboratory data, we can 
not perform multivariable analysis to show the most influencing 
variables. We do Z-test between NLR to other laboratory 
parameters to compare the accuracy. Statistically significant 
was considered using two-sided α less than 0.05. Statistical 
analysis was done using the IBM SPSS software (version 13).  
 
Results 
Patients Characteristic and Comparative Test  
The patient's baseline characteristics, early laboratory test, and 
comparative test results are presented in Table 1. A total of 423 
patients who met the criteria for participating had a median age 
of 54 (IQR 45-61) years. Patients in the discharge group have 
lower age (51.00  vs. 55.00; P =0.000) and higher length of 
hospitalization (15.00 vs. 5.00; P =0.000) than patients in the 
death group. There is no significant difference in mortality 
between male and female patients (P =0.514). The discharge 
group has significantly lower value than death group for WBC 
(7.71 vs 10.80; P =0.000), NLR (4.43 vs 9.32; P=0.000), PCT 
(0.13 vs 0.39; P =0.000), D-Dimer (1010.00 vs 2560.00; P 
=0.000) and CRP (6.00 vs 15.00; P =0.000) parameters.  
 
Table 1. Baseline Characteristic and Early Laboratory Test of The Study Cohort 
Variables Total (n=341) Discharge (n=193) Death (n=148) p-value 







Sex    0.514 
     Male 189 (55%) 104 (54%) 85 (57%)  
     Female 152 (45%) 89 (46%) 63 (43%)  
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Survival Analysis  
As seen in Figure 1, by using old age criteria and prespecified 
cut-off (obtained from the diagnostic tools) for laboratory 
parameters, we compare the survival probability between 
discharge and death group using Kaplan-Meier Survival Curve. 
Patients with older age (>59 years), higher WBC (>10.000/ul), 
NLR(>5), PCT (>0.5 ng/ml), d-dimer (>440 ng/ml), and CRP 
(>1 mg/dl) seem more vulnerable with lower survival during 
hospitalization. Patients older than 59 years have a significantly 
lower survival than patients younger than 59 years. Table 2  
 
shows that all laboratory parameters predict patient mortality 
during hospitalization. Each addition of one year's age would 
increase 1.027 (95% CI: 1.013-1.040; P=0.000) times of 
mortality risk. The HR of other laboratory parameters are 1.041 
(95% CI: 1.025-1.057; P =0.000) for WBC, 1.020 (95% CI: 
1.010-1.030; P =0.000) for NLR, 1.047 (95% CI: 1.024-1.070; 
P =0.000) for PCT, 1.000 (95% CI: 1.000-1.000; P =0.012) for 
d-dimer, and 1.004 (95% CI: 0.998-1.009; P =0.209).  
 
Table 2. COX Regression Analysis of Predictive Variables 
Variables  HR (95% CI) p-value 
Age (year) 1.027 (1.013-1.040) 0.000** 
White Blood Cell Count (103/uL) (n= 325 Patients) 1.041 (1.025-1.057) 0.000** 
Neutrophil Lymphocyte Ratio (n= 325 Patients) 1.020 (1.010-1.030) 0.000** 
Procalcitonin (ng/ml) (n= 249 Patients) 1.047 (1.024-1.070) 0.000** 
D-Dimer (ng/ml) (n= 184 Patients) 1.000 (1.000-1.000) 0.012* 
C-Reactive Protein (mg/dL) (n= 111 Patients) 1.004 (0.998-1.009) 0.209 
HR = Hazard Ratio; *p-value<0.05; ** p-value<0.01 
 
ROC Analysis and Comparison of AUC value   
The AUC value of all variables is shown in Figure 2. Age has 
an AUC value of 0.633, a low accuracy category (0.6-0.7). The 
early laboratory parameter, WBC, NLR, procalcitonin, d-dimer, 
and CRP, have moderate accuracy (0.7-0.8). NLR accuracy is 





with a Z-test score of 3.527 (p=0.000). As shown in Table 3, we 
found a more excellent AUC value on NLR but no significant 
Z-test in other comparisons. As a result, NLR was comparable 
to other laboratory parameters in predicting COVID-19 patient 
mortality.  
Table 3. Comparison of area under the curve of neutrophil-lymphocyte ratio to other parameters 
Variables AUC of NLR AUC of Comparator Z-test p-value 
NLR vs Age 0.773  
(0.722-0.824) 
0.633 (0.574-0.692) 3.527 0.000** 
NLR vs. WBC 0.709 (0.652-0.767) 1.643 0.100 
NLR vs PCT 0.738 (0.674-0.802) 0.833 0.405 
NLR vs D-Dimer 0.721 (0.649-0.794) 1.150 0.250 
NLR vs CRP 0.769 (0.679-0.858) 0.076 0.939 
AUC = Area Under the Curve; CRP = C-Reactive Protein; NLR = Neutrophil-Lymphocyte Ratio; PCT = Procalcitonin; WBC = White Blood Cells; **p-value<0.001 
 
Discussion  
The increasing demand for managing COVID-19 cases has 
burdened medical healthcare systems. Implementing good 
triage by early identification of a patient's prognosis is essential 
to improve COVID-19 patient management. In this study, the 
high mortality percentage (43.4%) might be caused by higher 
severe cases in Dr. Soetomo General Hospital due to its 
function as a national referral hospital. We found that all the 
variables involved in the patients' survival can be a predictor 
with low-moderate accuracy. We also found that  NLR was 
comparable to other laboratory parameters in predicting 
COVID-19 patient mortality. Previous studies have reported the 
association between older age and COVID-19 mortality [16–
18]. We confirmed that patients with older age have lower 
survival during hospitalization. The decrease of immunity 
function due to immunosenescence may be involved in a 
patient's condition [19]. In addition, the elderly appears to 
develop sub-clinical chronic inflammation conditions, called 
inflame-aging, after viral or other pathogens infections [20]. 
The consequence of inflame-aging is deleterious effet to organ 
leading to a higher risk of mortality [21]. Consistent with other 
studies, our findings reported that patients with higher WBC  
 
 
count, NLR, PCT, D-Dimer, and CRP had higher odds of 
COVID-19 mortality [5,22,23]. Although several studies 
declare no significant result on the association of higher WBC 
with the severity, higher WBC  may impact higher neutrophils 
cells which have a role in inflammation [23,24]. The higher 
NLR reflects the increase in pro-inflammatory cells and 
decreased lymphocytes and regulatory T cells, which have a 
role in controlling inflammation [22,25]. The use of PCT and 
CRP in COVID-19 patients may be based on their capability in 
detecting sepsis conditions [26,27]. The PCT showed high 
accuracy, while the CRP showed moderate accuracy in 
predicting sepsis [28]. Interestingly, these are also similar to the 
accuracy of both parameters in predicting COVID-19 severity, 
with the high accuracy for PCT and moderate accuracy for CRP 
[13]. D-dimer is also one of the standard parameters tested in 
COVID-19 patients. The significant association may be based 
on the potency of D-dimer to detect coagulopathy, the risk for 
venous thromboembolism,  and excessive inflammation in 
COVID-19 infection [29]. The survival analysis shows the 
significance of all variables in determining the patient's 
mortality risk. 















Figure 1. Kaplan-Meier Survival Curve of (A) Age (B) White Blood Cell Count (C) Neutrophil-Lymphocyte Ratio (D) Procalcitonin (E) D-Dimer (F) C-Reactive 
Protein for COVID-19 Patients Survival 
 
This can be explained since all the variables are associated with 
inflammation [30]. Inflammation is responsible for the 
progression of tissue damage and organ injury, from mild to 
severe organ dysfunction leading to poor outcomes [31,32]. 
Sepsis and other organ dysfunction appear as complication and 
mortality cause in COVID-19 patients [33,34]. ROC curve 
analysis reveals low accuracy of age and moderate accuracy of 
all laboratory markers on predicting mortality of COVID-19 
patients. The NLR has the highest accuracy with AUC 0.734 
(95%CI 0.675-0.793). This result is quite different from other 
studies reporting higher accuracy of PCT than other parameters 
[13], even though all the markers still show a significant 
accuracy to predict COVID-19 patient mortality. Z-test also 
showed no significant difference in accuracy between all  
 
laboratory markers, interpreted as all these markers have the 
same moderate accuracy in predicting COVID1-9 mortality. 
Hence, our study still recommends using conventional 
parameters, like WBC and NLR, for predicting the mortality of 
COVID-19, with better accessibility, feasibility, and affordable 
price, especially in developing countries. Until now, there are 
still few studies focused on analysis survival and predictive 
factors for COVID-19 mortality from developing countries in 
Southeast Asia. Our strength is to show the survival and 
predictive value of the conventional and "advanced" laboratory 
parameters. Therefore, our result can be used as a reference, 
especially for the developing countries which needed effective 
parameters with relatively low-cost expenditure.  
 
Log-rank P  = 0.028 Log-rank P  = 0.000 
Log-rank P  = 0.000 
Log-rank P  = 0.004 Log-rank P  = 0.017 
Log-rank P  = 0.000 
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Limitation of study 
Several limitations exist in our study. First, due to the limited 
sample tested by the "advanced" laboratory parameters, our 
accuracy comparison only can be conducted indirectly using the 
Z-test. Second, we cannot do the multivariate analysis due to 
the unequal sample size of each parameter. Finally, the 
investigators could not include other variables that may 




In conclusion, our study found a significant association between 
age and all laboratory markers (WBC, NLR, PCT, D-Dimer, 
and CRP) and COVID-19 patient mortality. All laboratory 
markers showed moderate accuracy as early predictors.  
 
However, our study still suggests routine complete blood count 
tests as prognostic biomarkers with moderate accuracy and the 
highest feasibility to be performed in developing countries. 
Further research may look into comparing all these parameters 
with radiological markers or specific clinical conditions to 




COVID-19: Coronavirus Disease 2019; WBC: White Blood 
Cells; NLR: Neutrophil-Lymphocyte Ratio; PCT: Procalcitonin; 
CRP: C-Reactive Protein; AUC: Area Under the Curve; RT-
PCR: Real-Time Polymerase Chain Reaction; SARS-CoV-2: 
Severe Acute Respiratory Syndrome Coronavirus 2; IQR: 













Figure 2. Receiver Operating Characteristic Curve of (A) Age (B) White Blood Cell Count (WBC) (C) Neutrophil-Lymphocyte Ratio (NLR) (D) Procalcitonin (PCT) (E) 
D-Dimer (F) C-Reactive Protein (CRP) for Prediction of COVID-19 Mortality 
Age 
AUC 0.633; P =0.000 
WBC 
AUC 0.709; P =0.000 
NLR 
AUC 0.773; P =0.000 
PCT 
AUC 0.738; P =0.000 
D-Dimer 
AUC 0.721; P =0.000 
CRP 
AUC 0.769; P =0.000 
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